Lumibird reports sales of 43.9 million euros for the first quarter of 2024, up 7.5% on a reported basis and 4.5% at constant exchange rates and scope of consolidation (excluding Convergent sales).

In organic terms, the laser technology specialist claims growth of 3% for its photonics division, driven by a 16% increase in the industrial and scientific segment, and 5.7% for its medical division.

With the gradual lifting of the few obstacles encountered at the end of 2023, and the ramp-up of new defense contracts, the Group claims to be on a strong growth trajectory, and confirms that it is targeting organic growth of at least 8% for 2024.

Copyright (c) 2024 CercleFinance.com. All rights reserved.